PBI 4050

BI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis indications being pursued for PBI-4050 include Idiopathic Pulmonary Fibrosis (IPF), Alström syndrome, Chronic Kidney Diseases (CKD)/Diabetic Kidney Diseases(DKD), Metabolic Syndrome and much more...

  • Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.

    Read Article
  • Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress

    Read Article
  • Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference

    Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference

    Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.

    Read Article
  • Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

    Read Article
  • PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    Prometic is hosting a key opinion leader luncheon to discuss our lead candidate PBI-4050 for Alstrom Syndrome and a promising therapeutic candidate for NASH

    Read PDF
  • Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).

    Read Article
  • Prometic reports second quarter 2018 financial results and highlights

    Prometic reports second quarter 2018 financial results and highlights

    Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read Article
  • Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.

    Read Article
  • Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).

    Read Article
  • Prometic presents new clinical data on PBI-4050 for the treatment of Idiopathic Pulmonary Fibrosis

    Prometic presents new clinical data on PBI-4050 for the treatment of Idiopathic Pulmonary Fibrosis

    Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity

    Read Article
  • Prometic reports its 2018 first quarter highlights and financial results

    Prometic reports its 2018 first quarter highlights and financial results

    Clinical programs streamlined to manage costs for balance of 2018 and continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions

    Read Article
  • Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial

    Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial

    Prometic received clearance by Health Canada to commence a placebo-controlled phase 2 clinical trial with PBI-4050 in patients with metabolic syndrome and type 2 diabetes.

    Read Article
  • Prometic presents new PBI-4050 clinical data from ongoing Alström Syndrome phase 2 trial

    Prometic presents new PBI-4050 clinical data from ongoing Alström Syndrome phase 2 trial

    Clinical activity measured in the heart, liver, kidney and fat tissue in patients treated with PBI-4050 over an average of 52 weeks

    Read Article
  • Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients

    Prometic reports positive clinical data from ongoing PBI-4050 study in Alström Syndrome patients

    Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment

    Read Article
  • Prometic to host key opinion leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)

    Prometic to host key opinion leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)

    The meeting will feature presentations to discuss the current treatment landscape, as well as the unmet medical need for treating patients with IPF.

    Read Article
  • Prometic reports its Q4-2017 and annual 2017 financial results and provides update on activities

    Prometic reports its Q4-2017 and annual 2017 financial results and provides update on activities

    Lead drug candidates PBI-4050 and Ryplazim™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data

    Read Article
  • Prometic announces publication of PBI-4050’s novel antifibrotic mechanism of action in American Journal of Pathology

    Prometic announces publication of PBI-4050’s novel antifibrotic mechanism of action in American Journal of Pathology

    PBI-4050’s anti-fibrotic mechanism of action demonstrated to occur via simultaneous stimulation of GPR40 and inhibition of GPR84

    Read Article
  • Prometic’s PBI-4050: phase 3 pivotal clinical trial design for Idiopathic Pulmonary Fibrosis (IPF) finalized

    Prometic’s PBI-4050: phase 3 pivotal clinical trial design for Idiopathic Pulmonary Fibrosis (IPF) finalized

    Prometic announces today the outcome of a successful clinical development Type C meeting with the US Food and Drug Administration for its orally active anti-fibrotic lead drug candidate, PBI-4050.

    Read Article
  • Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.

    Read Article
  • Prometic’s PBI-4050 receives Promising Innovative Medicine (PIM) designation from the UK MHRA in the treatment of IPF

    Prometic’s PBI-4050 receives Promising Innovative Medicine (PIM) designation from the UK MHRA in the treatment of IPF

    We are proud to have received a second PIM designation in the UK for PBI-4050, following the designation previously received for Alström syndrome.

    Read Article
  • loading
    Loading More...